临时植入镍钛装置治疗良性前列腺梗阻的3年随访
一项前瞻性研究纳入32例良性前列腺增生相关下尿路症状患者,植入临时镍钛装置(TIND)并随访36个月。结果显示IPSS、QoL及Qmax较基线持续显著改善,无远期并发症,提示TIND至少36个月内安全有效且耐受良好。
要点
- TIND植入后36个月Qmax较基线升高41%(均值10.1 mL/s)。
- IPSS中位数从基线19降至36个月时12,QoL从3降至2。
- 早期并发症4例(12.5%),36个月随访期间无新增并发症。
核心结论
- 延长随访至36个月证实TIND植入安全、有效且耐受良好。
研究设计与样本
- 前瞻性研究,纳入32例有下尿路症状的BPH患者,在膀胱颈和前列腺尿道植入TIND,5天后门诊取出。
- 纳入标准:年龄>50岁,IPSS≥10,Qmax<12 mL/s,前列腺体积<60 mL。
- 随访时间点:3、6周及3、6、12、24、36个月。
主要发现
- 基线平均年龄69.4(8.2)岁,前列腺体积29.5(7.4)mL,Qmax 7.6(2.2)mL/s;IPSS中位数19(IQR 14-23),QoL评分中位数3(IQR 3-4)。
- 所有植入成功,平均总手术时间5.8 min,无术中并发症。
- IPSS、QoL评分和Qmax在每次随访时较基线变化均显著。
- 36个月随访时Qmax平均10.1 mL/s,较基线升高41%;IPSS中位数12(IQR 6-24),QoL中位数2(IQR 1-4)。
- 早期并发症4例(12.5%):尿潴留1例(3.1%)、装置移位致暂时性尿失禁1例(3.1%)、感染2例(6.2%);36个月随访期间无其他并发症。
临床怎么用
- 对于前列腺体积<60 mL、以LUTS为主的BPH患者,TIND植入可作为微创治疗选择,至少36个月随访显示持续改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report 3-year follow-up results of the first implantations with a temporary implantable nitinol device (TIND® ; Medi-Tate Ltd., Or Akiva, Israel) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: In all, 32 patients with LUTS were enrolled in this prospective study. The study was approved by the local Ethics Committee. Inclusion criteria were: age >50 years, International Prostate Symptom Score (IPSS) ≥10, peak urinary flow (Qmax ) <12 mL/s, and prostate volume <60 mL. The TIND was implanted within the bladder neck and the prostatic urethra under light sedation, and removed 5 days later in an outpatient setting. Demographics, perioperative results, complications (according to Clavien-Dindo classification), functional results, and quality of life (QoL) were evaluated. Follow-up assessments were made at 3 and 6 weeks, and 3, 6, 12, 24 and 36 months after the implantation. The Student's t-test, one-way analysis of variance and Kruskal-Wallis tests were used for statistical analyses. RESULTS: At baseline, the mean (standard deviation, sd) patient age was 69.4 (8.2) years, prostate volume was 29.5 (7.4) mL, and Qmax was 7.6 (2.2) mL/s. The median (interquartile range, IQR) IPSS was 19 (14-23) and the QoL score was 3 (3-4). All the implantations were successful, with a mean total operative time of 5.8 min. No intraoperative complications were recorded. The change from baseline in IPSS, QoL score and Qmax was significant at every follow-up time point. After 36 months of follow-up, a 41% rise in Qmax was achieved (mean 10.1 mL/s), the median (IQR) IPSS was 12 (6-24) and the IPSS QoL was 2 (1-4). Four early complications (12.5%) were recorded, including one case of urinary retention (3.1%), one case of transient incontinence due to device displacement (3.1%), and two cases of infection (6.2%). No further complications were recorded during the 36-month follow-up. CONCLUSIONS: The extended follow-up period corroborated our previous findings and suggests that TIND implantation is safe, effective and well-tolerated, for at least 36 months after treatment.
引用
- Porpiglia F, Fiori C, Bertolo R, et al. 3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int. 2018. PMID: 29359881. doi:10.1111/bju.14141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。